Comparative Pharmacology
Head-to-head clinical analysis: LOVENOX versus LOVENOX PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOVENOX versus LOVENOX PRESERVATIVE FREE.
LOVENOX vs LOVENOX (PRESERVATIVE FREE)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Low molecular weight heparin (LMWH) that binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin, thereby preventing thrombus formation.
Low molecular weight heparin (LMWH) that potentiates antithrombin III, accelerating inactivation of factor Xa and thrombin.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis in abdominal surgery, hip or knee replacement; 30 mg subcutaneously every 12 hours for prophylaxis in medical patients; 0.5 mg/kg subcutaneously once daily for prophylaxis in patients with acute coronary syndrome.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily.
None Documented
None Documented
Terminal half-life: 4.5-7 hours after subcutaneous administration; prolonged in renal impairment (up to 16 hours with CrCl <30 mL/min), requiring dose adjustment.
Terminal half-life: 3-5 hours after subcutaneous injection; prolonged in renal impairment (up to 8-10 hours with CrCl <30 mL/min).
Renal: 40-60% as active and inactive fragments via glomerular filtration and tubular secretion; biliary/fecal: minimal, <10%.
Renal: 40-60% as unchanged drug and low molecular weight fragments via glomerular filtration; biliary/fecal: negligible.
Category C
Category C
Low Molecular Weight Heparin
Low Molecular Weight Heparin